HIV transmission in serodiscordant heterosexual couples

Boily, Marie-Claude; Buvé, Anne; Baggaley, Rebecca F.
May 2010
BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/29/2010, Vol. 340 Issue 7757, p1149
Academic Journal
The authors comment on a study discussed within the issue which estimated the risk of heterosexual transmission of HIV-1 from infected patients taking combined antiretroviral treatment. As stated, participants were assigned to immediate antiretroviral treatment or deferred treatment when their CD4 count drops below 250 cells per microliter. A review of the related literature is also offered. The authors consider the possible implication of the findings on counselling serodiscordant couples.


Related Articles

  • ART prevented HIV transmission in serodiscordant couples.  // Infectious Disease News;Jan2013, Vol. 26 Issue 1, p8 

    The article presents a study conducted by Chinese researchers, which showed that providing antiretroviral therapy (ART) to the HIV-positive partner in a serodiscordant couple lowered the rate of HIV transmission to the uninfected partner.

  • WHO OPTS OUT OF HIV TESTING. Ward, Helen; Miller, Rob // Sexually Transmitted Infections;Aug2009, Vol. 85 Issue 4, p1 

    The article reports on the significance of introducing the HIV testing in protecting heterosexual people from the risks of HIV infection in Amsterdam, Netherlands. The introduction of HIV testing is specifically intended to identify persons diagnosed with HIV infection to offer them assistance...

  • Characteristics of HIV-1 Discordant Couples Enrolled in a Trial of HSV-2 Suppression to Reduce HIV-1 Transmission: The Partners Study. Jairam R. Lingappa; Erin Kahle; Nelly Mugo; Andrew Mujugira; Amalia Magaret; Baeten, Jared; Elizabeth A. Bukusi; Craig R. Cohen; Elly Katabira; Allan Ronald; Kiarie, James; Farquhar, Carey; Stewart, Grace John; Makhema, Joseph; Essex, M.; Were, Edwin; Fife, Kenneth; deBruyn, Guy; Gray, Glenda; McIntyre, James // PLoS ONE;2009, Vol. 4 Issue 4, p1 

    Background: The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires...

  • Pre-exposure prophylaxis in HIV. Khambhati, Ravi; Singhal, Priyanka; Marfatia, Y. S. // Indian Journal of Sexually Transmitted Diseases;2009, Vol. 30 Issue 2, p127 

    The article presents abstracts on medical topics which include a study on the use of HIV pre-exposure prophylaxis (HIV-PrEP) in HIV prevention, the efficacy of combined Tenofovir and Emtricitabine as HIV-PrEP to reduce the risk of HIV transmission in the U.S., and the impact of antiretroviral...

  • Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. Ingle, Suzanne M.; May, Margaret T.; Gill, M. John; Mugavero, Michael J.; Lewden, Charlotte; Abgrall, Sophie; Fätkenheuer, Gerd; Reiss, Peter; Saag, Michael S.; Manzardo, Christian; Grabar, Sophie; Bruyand, Mathias; Moore, David; Mocroft, Amanda; Sterling, Timothy R.; D'Arminio Monforte, Antonella; Hernando, Victoria; Teira, Ramon; Guest, Jodie; Cavassini, Matthias // Clinical Infectious Diseases;Jul2014, Vol. 59 Issue 2, p287 

    Among HIV-infected patients who initiated antiretroviral therapy (ART), patterns of cause-specific death varied by ART duration and were strongly related to age, sex, and transmission risk group. Deaths from non-AIDS malignancies were much more frequent than those from cardiovascular...

  • Global: clinical trial shows dramatic reduction in transmission of HIV as a result of treatment. Cozac, David // HIV/AIDS Policy & Law Review;Oct2011, Vol. 15 Issue 3, p31 

    The article reports on a clinical trial conducted by the U.S. HIV Prevention Trials Network which revealed that human immunopdeficiency virus (HIV)-positive persons' adherence to an effective antiretroviral therapy reduce the risk of virus transmission by 96 percent. The trial confirmed that HIV...

  • Access to HIV/AIDS therapy widens down under.  // PharmacoEconomics & Outcomes News;6/18/2005, Issue 480, p18 

    Reports on the decision of the New Zealand drug funding agency Pharmac to provide HIV-positive persons access to the fixed combination antiretroviral agent lopinavir/ritonavir Kaletra. Plan of the agency to extend the use of antiretrovirals to help prevent mother-to-child transmission of HIV...

  • The Impact of Opiate Substitution Therapy and Highly Active Antiretroviral Therapy on Mortality Risk Among People Who Inject Drugs. Hickman, Matthew; Vickerman, Peter; Degenhardt, Louisa // Clinical Infectious Diseases;10/1/2015, Vol. 61 Issue 7, p1166 

    The authors discuss the impact of opiate substitution therapy and antiretroviral therapy on mortality risk in people who inject drugs (PWID). Topics discussed include role of opioid substitution therapy in reducing the risk of HIV transmission among PWID, role of antiretroviral therapy in...

  • Infección por Virus de la Inmunodeficiencia Humana: Experiencia en el Hospital Infantil del Estado de Sonora de 1994 a 2007. Dorame-Castillo, Roberto; Cano-Rangel, Manuel Alberto; De Los Ángeles Durazo-A., María; Contreras-Soto, Jesús // Boletin Clinico Hospital Infantil del Estado de Sonora;2008, Vol. 25 Issue 1, p22 

    Objective: To make a retrospective review of patients treated for HIV (human immunodeficiency virus) carrier or AIDS in the service infectology service at the Sonora Children Hospital in 1994 thru 2007 period. Material and Methods: We reviewed the records of 25 patients diagnosed with HIV...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics